Prostacyclin biosynthesis in activated, stimulated and normal mouse peritoneal cell populations.
Nonspecific resistance to infectious and neoplastic disease can be enhanced by administration of "immunomodulators". The levels of enhancement can be monitored by following in vitro function of cells of the lympho-reticuloendothelial system. To gain a better understanding of the physiological and biochemical nature of this enhancement, the metabolism of prostaglandin endoperoxide PGH2 was followed in mouse peritoneal cells (PCs). Homogenates of PCs from normal, unstimulated mice yielded primarily prostacyclin (PGI2) when incubated with PGH2. Homogenates of PCs from mice injected with the immunomodulators C. parvum, levamisole HCl, pyran copolymer, or thioglycollate yielded less PGI2. Reductions ranged from 73% for C. parvum to 32% for levamisole. A statistically significant inverse correlation existed between the level of macrophage "activation" and ability of cellular homogenates to produce prostacyclin. The results suggest that prostacyclin may be involved in modulation of nonspecific resistance.
D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D011464:Epoprostenol / Q000096:biosynthesis* / Q000494:pharmacology; D005260:Female; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism*; D008264:Macrophages / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D010587:Phagocytosis / Q000187:drug effects; D011449:Prostaglandin Endoperoxides / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011453:Prostaglandins / Q000096:biosynthesis*; D014780:Viruses / Q000187:drug effects
D011449:Prostaglandin Endoperoxides; D011453:Prostaglandins; D011464:Epoprostenol; D011451:Prostaglandin-Endoperoxide Synthases